Clinical trial · Interventional
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Conducting an Early Phase Clinical Trial to Assess for CEA Antigen Presentation Therapeutic Biological Product Mix Activity That Suggests the Potential for Clinical Benefits of CEA Positive Rectal Cancer Patients.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activate human CEA Protein Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the CEA protein antigen into small peptide fragments, and then kill CEA positive rectal cancer cells in vivo.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CEA protein antigen plus BCG Vaccine Mix for percutaneous use | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Assess for CEA Antigen Presentation Therapeutic Biological Product Mix activity
- description
- CEA protein antigen 0.05 mg add into BCG Organism 50 MG
- interventionNames
- Biological: CEA protein antigen plus BCG Vaccine Mix for percutaneous use
Primary outcomes (3)
- measure
- 20 Rectal Cancer Participants with CEA blood test
- timeFrame
- Duration up to 90 days
- description
- Positive testing CEA by blood-drawing
- measure
- 20 Rectal Cancer Participants with IGRA blood test with CEA protein antigen
- timeFrame
- Duration up to 90 days
- description
- Positive IGRA blood test with CEA protein antigen after percutaneous use 21 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 24 Years
- Maximum age
- 64 Years
Show eligibility criteria text
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 20 CEA Positive Rectal Cancer Patients Inclusion Criteria: * Clinical Rectal Cancer Diagnosis Stage 0 - IIA * Clinical Rectal Cancer Diagnosis without symptoms * Clinical Rectal Cancer Diagnosis without metastasis * Positive testing CEA by blood-drawing * TB negative participant is negative IGRA blood test with TB antigens. Exclusion Criteria: * Pregnant * Thrombosis * Allergy * TB positive participant is positive IGRA blood test with TB antigens. * Symptoms of rectal cancer * Metastasis of rectal cancer * Evidence of critical illness
References
Publications (0)
Data not yet available